Climb Bio (CLYM) Free Cash Flow (2020 - 2026)

Climb Bio has reported Free Cash Flow for 7 years, with the latest figure at -$14.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 6.84% year-over-year to -$14.4 million; the trailing twelve-month figure through Mar 2026 stood at -$53.4 million (down 83.06% YoY), and the FY2025 full-year result was -$54.5 million, down 250.48% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$14.4 million, up from -$15.6 million in the prior quarter.
• The five-year high for Free Cash Flow was $3.5 million in Q3 2023, with the low at -$15.6 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$8.4 million across 5 years, with a median of -$8.4 million in 2022.
• Annual changes were most pronounced in 2023 — Free Cash Flow jumped 183.59% — and 2025, when it tumbled 1571.36%.
• Climb Bio's Free Cash Flow stood at -$8.4 million in 2022, then jumped by 88.79% to -$947000.0 in 2023, then sank by 483.0% to -$5.5 million in 2024, then tumbled by 183.19% to -$15.6 million in 2025, then increased by 8.03% to -$14.4 million in 2026.
• The last three Free Cash Flow figures came in at -$14.4 million (Q1 2026), -$15.6 million (Q4 2025), and -$12.2 million (Q3 2025), per Business Quant data.